Bani-Hani Kamal E
Surgical Department, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan.
Saudi Med J. 2002 Apr;23(4):379-83.
We present a review of the current status of Helicobacter pylori infection, and focus on the clinical issues facing physicians with regards to its pathogenicity, diagnosis and treatment. We have attempted to address the important clinical issues relevant to the subject, and summarize the currently accepted concepts concerning Helicobacter pylori. Our knowledge regarding Helicobacter pylori biology is enormous, but detailed knowledge on its transmission is still far from clear. Helicobacter pylori is mainly involved in gastrointestinal and possibly in other extra-intestinal disorders. There are differences in the clinical presentation in various geographical regions resulting from variations in the genetic make-up of Helicobacter pylori. There is still need for more simple, cost-effective, accurate and less invasive diagnostic techniques. The gold standard treatment is the one-week proton pump inhibitor-based triple regimen as first line, with quadruple therapy as a 2nd line. Helicobacter pylori resistance to the main antimicrobials needs to be defined in particular geographical areas.
我们对幽门螺杆菌感染的现状进行了综述，并重点关注医生在其致病性、诊断和治疗方面面临的临床问题。我们试图解决与该主题相关的重要临床问题，并总结目前关于幽门螺杆菌的公认概念。我们对幽门螺杆菌生物学的了解很多，但对其传播的详细了解仍远不清楚。幽门螺杆菌主要涉及胃肠道疾病，也可能涉及其他肠道外疾病。由于幽门螺杆菌基因构成的差异，不同地理区域的临床表现存在差异。仍然需要更简单、经济高效、准确且侵入性较小的诊断技术。金标准治疗是一线采用基于质子泵抑制剂的一周三联疗法，二线采用四联疗法。需要确定幽门螺杆菌在特定地理区域对主要抗菌药物的耐药情况。
